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1. Introduction  
Hypercalcemia is one of the most common paraneoplastic syndromes. The incidence of 
hypercalcemia is 50-90% in adult T-cell leukemia/lymphoma (ATLL), 27-35% in lung 
cancer, 25-30% in breast cancer, 7-30% in multiple myeloma, and less than 10% in other 
types of cancer patients (Mundy & Martin, 1982; Roodman, 1997). Patients with severe 
hypercalcemia (>12 mg/dL; > 6.0 mM) usually develop neuromuscular, gastrointestinal and 
renal symptoms including lethargy, depression, anorexia, nausea, vomiting, polyuria and 
polydipsia. Patients with serum calcium concentrations >15 mg/dL (7.6 mM) can develop 
renal failure or cardiovascular abnormalities with arrhythmias and coma (Mundy & Martin, 
1982). Depending on the sources of the stimulating factors, hypercalcemia in cancer can be 
divided into 3 types: (1) humoral hypercalcemia of malignancy (HHM) in which humoral 
factors secreted by tumor cells directly or indirectly affect cells in the target organs including 
bone, kidney and intestine that regulate calcium homeostasis; (2) local osteolytic 
hypercalcemia in which factors secreted by either primary or metastatic tumor cells locally 
in the bone microenvironment stimulate osteoclastic bone resorption; and (3) primary 
hyperparathyroidism that coexists with the malignancy (Stewart, 2005). This review will 
focus on HHM, although some types of cancers may induce both HHM and local osteolytic 
hypercalcemia, since several factors can function both systemically and locally.   
2. Overview of humoral hypercalcemia of malignancy 
Humoral hypercalcemia of malignancy (HHM) is characterized by (1) circulating humoral 
factors derived from cancer cells; (2) uncoupling of bone formation and bone resorption; (3) 
increased renal calcium reabsorption even though there is hypercalciuria caused by 
increased Ca2+ in the glomerular filtrate. In contrast to HHM in primary 
hyperparathyroidism, bone formation and resorption are both increased resulting in fibrous 
osteodystrophy in patients with longstanding disease.  
HHM is a common complication of certain lymphoma/leukemias; squamous cell 
carcinomas (e.g., of the lung or other organs); renal and breast carcinomas, and occasionally 
other tumors (Stewart, 2002). Factors secreted by the cancer cells (see Table 1 below) 
stimulate osteoclastic bone resorption (directly or indirectly through osteoblasts) by 
increasing the activity and/or survival of osteoclast precursors or mature osteoclasts. Most 
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cancer-derived hypercalcemic factors stimulate osteoclastic bone resorption indirectly by 
inducing osteoclast-stimulating factors from osteoblasts or bone stromal cells. Under normal 
physiological conditions, increased serum calcium concentration can be compensated for by 
decreasing the intestinal calcium absorption, increasing renal calcium excretion, decreasing 
PTH secretion from the parathyroid glands, and decreasing bone resorption. However, 
secretion of the cancer-related factor, parathyroid hormone-related protein (PTHrP), also 
increases renal calcium reabsorption in the kidney through the activation of parathyroid 
hormone receptor 1 (PTH1R), which facilitates the development of HHM. 
 
Factors Origin Target cells/molecule Function in bone 
PTHrP Cancer cells Osteoblast 
Catabolic and 
anabolic 
RANKL 
Osteoblast, 
cancer cells 
Osteoclast Catabolic 
OPG Osteoblast RANKL Inhibit RANKL 
MIP-1 Cancer cells Osteoblast Catabolic 
Calcitriol 
Kidney, 
cancer cells, 
tumor-
associated 
macrophages 
Intestines, kidney, 
osteoclast, osteoblast, 
parathyroid chief cells 
Increases calcium in 
blood 
TNF-ǂ, IL-1, IL-6, IL-17 T-cells Osteoclast Catabolic 
OPG, IL-3, IL-4, IL-10, 
IL-13, IFN-ǃ, IFN-Ǆ, 
GM-CSF, and sFRPs 
T-cells Osteoclast 
Inhibit osteoclast 
formation and/or  
function 
Calcium (Ca+2) 
Bone 
Kidney 
Intestinal 
tract 
Calcium-sensing 
receptor (CaR) on 
bone and cancer cells 
and parathyroid chief 
cells 
Anabolic (bone cells) 
Catabolic (cancer 
cells) Decreases PTH 
secretion 
Table 1. Factors associated with HHM that cause bone formation (anabolic action) or 
resorption (catabolic action) in bone. 
3. Factors involved in the pathogenesis of HHM 
3.1 Parathyroid hormone-related protein (PTHrP) 
PTHrP was first cloned by Suva et al. (Suva et al.,  1987) and purified by Broadus et al. 
(Broadus et al.,  1988). PTHrP is widely expressed in normal tissues and functions as an 
endocrine, autocrine, paracrine and intracrine hormone. PTHrP is a polyhormone that 
results from alternative mRNA splicing and post-translational proteolytic processing. 
During development, PTHrP is essential for the growth and regulation of endochondral 
bone (Karaplis et al.,  1994; Wysolmerski et al.,  1998), epithelial-mesenchymal interactions 
in mammary gland (Wysolmerski et al.,  1998), and has important functions in many other 
tissues. PTHrP knockout mice die soon after birth due to asphyxia caused by developmental 
abnormalities of bones in the thorax (Karaplis et al.,  1994). PTHrP has been shown to be the 
principal factor in most cases of cancer-induced HHM. The expression of PTHrP is up-
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regulated by NF-κB, TGF-ǃ, and/or Ras-MAPK signaling (Nadella et al.,  2007; Richard et 
al.,  2005). In adult T-cell leukemia/lymphoma, the promoter of PTHrP can be activated by 
the binding of HTLV-1 oncoprotein, Tax (Ejima et al.,  1993; Watanabe et al.,  1990).  
The functions of PTHrP depend on the activation of different signal transduction pathways, 
including cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) and protein 
lipase C/protein kinase C (PLC/PKC) cascades. In addition, PTHrP fragments have 
different functions that depend on the tissue-specific expression of distinct receptors. 
Activation of the cAMP-PKA pathway is required for PTHrP to induce bone resorption 
through the PTH1R, which recognizes both PTH and PTHrP (Greenfield et al.,  1995).  
Besides the catabolic effect of PTHrP on bone, intermittent administration or pulsatile 
secretion of the N-terminal fragment of PTH (1-34) and PTHrP (1-36) by a neuroendocrine 
tumor, such as islet cell carcinoma, can induce bone anabolic effects (Takeuchi et al.,  2002). 
When osteoblastic cells were transiently exposed to the C-terminus of PTHrP (107-139), 
anabolic effects were induced by the upregulation of vascular endothelial growth factor 
receptor 2 (VEGFR2) through PKC/ERK activation (de Gortazar et al.,  2006).  
3.2 Receptor activator of nuclear kappa-B ligand (RANKL) and osteoprotegerin (OPG) 
RANKL belongs to the tumor necrosis factor (TNF) family and represents one of the most 
common mediators for inducing osteoclastic bone resorption. Mature osteoblasts produce 
two forms of RANKL, a membrane-bound and secreted form. Both are important for 
osteoclast stimulation (Leibbrandt & Penninger, 2008). The expression of RANKL in 
osteoblasts and stromal cells is activated by the RUNX2 transcriptional factor under the 
regulation of PTHrP, 1,25-dihydroxyvitamin D3, and prostaglandins (Lipton et al.,  2009). 
RANKL binds and activates its receptor, RANK, which is expressed on the surface of 
osteoclasts. The binding of RANKL to RANK activates at least three major signaling 
pathways, NFAT, p38 and JNK, resulting in up-regulation of genes that are required for 
induction of osteoclast fusion, differentiation, activation and survival (Leibbrandt & 
Penninger, 2008). The secreted form of RANKL is important for the recruitment of osteoclast 
precursors and osteoclastogenesis. RANKL is an essential activator for normal bone 
remodeling. RANKL knockout mice have severe osteopetrosis (Lomaga et al.,  1999).  
OPG, or osteoclastogenesis inhibitory factor (OCIF), is a secreted member of the tumor 
necrosis receptor superfamily that is expressed by osteoblasts and functions as a RANKL 
‘decoy receptor’ (Simonet et al.,  1997). OPG binds to RANKL and blocks its interaction 
with RANK on osteoclast precursors (Lacey et al.,  1998); therefore, it is a potent inhibitor 
of osteoclast formation and bone resorption. OPG knockout mice have early-onset 
osteopenia (Bucay et al.,  1998; Mizuno et al.,  1998), whereas OPG overexpressing mice 
develop osteopetrosis that results from the failure to form osteoclasts (Simonet et al.,  
1997). PTH and PTHrP suppress OPG expression by downregulating the promoter of 
OPG through activation of the cAMP/PKA pathway (Yang et al.,  2002). PTHrP, on the 
other hand, stimulates RANKL expression to induce bone resorption. The ratio between 
RANKL and OPG levels in osteoblasts is a key factor in the regulation of osteoclast 
activity (Horwood et al.,  1998).  
In ATLL, the expression of RANKL in tumor cells correlated with hypercalcemia in patients. 
RANKL on the surface of leukemia cells induced osteoclastogenesis through direct contact 
with precursor cells (Nosaka et al.,  2002). The direct activation of osteoclasts by tumor cells 
may play a key role in the decoupling of bone formation and bone resorption in HMM. 
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Therefore, RANKL from either osteoblasts or tumor cells is an important mediator of bone 
resorption in many forms of HHM.  
3.3 Cytokines  
The increased secretion of inflammatory cytokines from cancer cells, such as tumor necrosis 
factor-ǂ (TNF-ǂ), IL-1, IL-6, IL-8, M-CSF, CCL2 and CXCL12, is one of the key mechanisms 
by which NF-κB is constitutively activated in tumor cells (Lu & Stark, 2004).  The 
proinflammatory cytokine, TNF-ǂ, is a critical factor in the pathogenesis of many 
inflammatory and non-inflammatory diseases which are characterized by increased 
osteoclastic bone resorption including rheumatoid arthritis (Chu et al.,  1991), osteoporosis 
(Horowitz, 1993), osteomyelitis (Meghji et al.,  1998) and aseptic loosening (an osteolysis 
syndrome caused by macrophages in joint replacements) (Merkel et al.,  1999). TNF-ǂ 
mediates lipopolysaccharide-stimulated osteoclastogenesis through the p55 receptor 
expressed on bone marrow macrophages and activation of NF-κB (Abu-Amer et al.,  1997; 
Abu-Amer et al.,  1998). Whether osteoclastogenesis induced by TNF-ǂ depends on RANKL 
or not remains controversial. Some studies have shown that without exogenous RANKL, 
TNF-ǂ is sufficient to induce osteoclast differentiation (Kudo et al.,  2002), and the increase 
of osteoclastogenesis was inhibited by OPG (Hounoki et al.,  2008). However, Boyle et al. 
have shown that administration of TNF-ǂ to RANK-deficient mice failed to induce 
osteoclastogenesis and restore hypocalcemia, suggesting that TNF-ǂ cannot substitute for 
RANKL (Li et al.,  2000). Teitelbaum et al. have reported that TNF-ǂ alone was not able to 
induce osteoclastogenesis in murine osteoclast precursors; rather, RANKL was required for 
TNF-ǂ to stimulate osteoclast precursors to form osteoclasts (Lam et al.,  2000). Regardless, 
TNF-ǂ has shown its potential to be a therapeutic target for bone resorption. Increased TNF-
ǂ levels have been found in patients with advanced chronic lymphocytic leukemia (CLL) 
and acute nonlymphocytic leukemia with HHM (Ferrajoli et al.,  2002).   
Increased plasma IL-6 has been found in cancer patients with HHM, including patients 
with multiple myeloma, squamous cell carcinoma of the liver, acute nonlymphocytic 
leukemia, and adult T-cell leukemia/lymphoma (Asanuma et al.,  2002; Kounami et al.,  
2004; Roodman, 1997). IL-6 increases osteoclast recruitment by binding to its receptor on 
osteoblasts and inducing the signal of transducer and activator of transcription (STAT)-
1/3 and mitogen-activated protein kinase (MAPK) signaling pathways (Sims et al.,  2004). 
It also enhances the effects of PTH and PTHrP and mediates the effects of inflammatory 
cytokines, such as IL-1 and TNF-ǂ, on osteoclast formation (Roodman, 2001). IL-6 does 
not directly increase RANKL expression; therefore, its osteoclastogenic effect is RANKL-
independent (Hofbauer et al.,  2000). However, there is no correlation between serum IL-6 
and HHM in cancer patients, suggesting that IL-6 functions additively or synergistically 
with other factors and may be a redundant factor for development of HHM 
(Vanderschueren et al.,  1994). 
Granulocyte macrophage-colony stimulating factor (GM-CSF) also plays a role in 
osteoclastogenesis and it has two distinct effects on osteoclast activity depending upon the 
presence of RANKL. GM-CSF increases the proliferation of osteoclast progenitors when 
RANKL is absent. On the other hand, it induces osteoclast progenitors to differentiate into 
dendritic cells when RANKL is present (Gillespie, 2007).  
Macrophage colony-stimulating factor (M-CSF) is essential for osteoclast differentiation and 
proliferation of osteoclast progenitor cells (Tanaka et al.,  1993). Increased serum M-CSF 
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concentration has been reported in acute nonlymphocytic leukemia patients with HHM 
(Kounami et al.,  2004).  
Interferon (IFN)-Ǆ disrupts JAK/STAT signaling in osteoblasts to induce the expression of 
OPG and Wnt, causing decreased cathepsin K and tartrate-resistant acid phosphatase 
(TRAP) in mature osteoclasts (Gallo et al.,  2008; Gillespie, 2007). Transgenic mice with the 
HTLV-1 viral oncoprotein, Tax, and knockout of IFN-Ǆ developed more severe osteolytic 
bone lesions and increased osteoclast activity. Administration of IFN-Ǆ to mice transplanted 
with Tax-positive tumors inhibited tumor growth and decreased hypercalcemia, suggesting 
a protective role for IFN-Ǆ in HHM development (Xu and Hurchla et al.,  2009).  
Cytokines have been shown to play a more important role in the pathogenesis of HHM in 
patients with lymphoma and leukemia compared to patients with carcinoma. However, 
further investigation is needed to clarify the additive and synergistic roles of cytokines in 
causing hypercalcemia because multiple cytokines are often produced by the tumor cells.  
3.4 Macrophage inflammatory protein-1 alpha (MIP-1α) 
MIP-1ǂ is a pro-inflammatory chemokine expressed by many different cell types 
including macrophages, dendritic cells and lymphocytes. It normally functions as a 
chemoattractant for T-cells, macrophages, and other proinflammatory cells at the site of 
inflammation. It also regulates the transendothelial migration of NK cells, monocytes and 
dendritic cells (Maurer & von, 2004). Therefore, it plays an important role in autoimmune 
and inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, asthma, and 
organ transplant rejection (Maurer & von, 2004). MIP-1ǂ binds to several chemokine (c-c 
motif) G-protein-coupled receptors including CCR1, CCR5 and CCR9, which are 
expressed in lymphocytes and monocytes/macrophages. It activates several signaling 
pathways, including PI3K, PLC, PKC, MAP kinase and JAK/STAT pathways (Tsubaki et 
al.,  2007). MIP-1ǂ can potently inhibit the binding of HIV to CCR5 on macrophages (Baba 
et al.,  1999; Maurer & von, 2004).  
Both CCR1 and CCR5 are expressed in bone marrow stromal cells. MIP-1ǂ is chemotactic 
for osteoclasts and osteoclast precursors (Fuller et al.,  1995). MIP-1ǂ was first identified 
as a putative osteoclastogenic factor in a human myeloma cDNA expression library 
derived from marrow samples of myeloma patients (Zlotnik & Yoshie, 2000). 
Subsequently, CCR1 and CCR5 expression was demonstrated in human and murine 
multiple myeloma cell lines (Menu et al.,  2006). Furthermore, MIP-1ǂ enhances osteoclast 
formation induced by IL-6, PTHrP and RANKL in multiple myeloma (Han et al.,  2001) 
and increases adhesion of myeloma cells to bone marrow cells through its binding to both 
CCR1 and CCR5 receptors (Oba et al.,  2005). In vivo, mice bearing Chinese hamster ovary 
cells that overexpress MIP-1ǂ develop more severe osteolytic lesions after intramuscular 
inoculation (Oyajobi et al.,  2003).  
The mechanisms by which MIP-1ǂ induces osteoclastic bone resorption are controversial. 
One study demonstrated that a RANKL-dependent pathway was responsible for activation 
of osteoclasts (Tsubaki et al.,  2007). MIP-1ǂ enhances RANKL expression in mouse bone 
marrow stromal cells and osteoblasts through the MAPK and PI3K/Akt signaling pathways. 
On the other hand, RANK-Fc did not block the activation of osteoclasts by MIP-1ǂ, 
indicating that MIP-1ǂ used a RANKL-independent pathway to increase bone resorption 
(Han et al.,  2001). Therefore, it has been suggested that MIP-1ǂ is a RANKL-independent 
osteoclastogenic factor that acts directly on osteoclast precursors (Choi et al.,  2000). In any 
case, it is apparent that MIP-1ǂ is a significant osteoclast activator. The role of MIP-1 in 
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HHM is highlighted by the fact that HTLV-1 infected T-cells express and secrete MIP-1ǂ 
(Shu et al.,  2007; Shu et al.,  2010), and the increased serum levels of MIP-1ǂ correlated well 
with the development of HHM in HTLV-1-infected patients (Okada et al.,  2004).   
3.5 1α,25-Dihydroxyvitamin D (Calcitriol) 
Vitamin D is an essential hormone for calcium homeostasis. Its active form, 1ǂ,25-
dihydroxyvitamin D3 or calcitriol, is synthesized by hydroxylation of vitamin D in the  
kidney. The renal 25-hydroxyvitamin D 1-ǂ hydroxylase is the rate limiting enzyme for 
production of calcitriol. Calcitriol increases calcium absorption from the intestinal tract, 
increases osteoclastic bone resorption, and decreases PTH gene expression in the 
parathyroid glands (Guise et al.,  2005). Calcitriol is an uncommon primary cause of HHM 
in patients with leukemia or lymphoma even though serum calcitriol concentrations may be 
increased in up to 50% of patients (Seymour & Gagel, 1993). Some lymphomas or tumor-
associated macrophages express 25-hydroxyvitamin D 1-ǂ hydroxylase, which is 
responsible for the increased production of calcitriol (Hewison et al.,  2003).  
3.6 Cell membrane calcium-sensing receptor (CaR) 
CaR is expressed on multiple cell types including the chief cells of the parathyroid gland 
where it regulates PTH expression and secretion. Under normal conditions, CaR, a G 
protein-coupled receptor, senses extracellular calcium concentrations and activates 
downstream signaling pathways, such as the PLC/inositol trisphosphate (IP3) and ERK1/2 
pathways, in a tissue-specific manner (Saidak et al.,  2009).  In bone, CaR is expressed in 
osteoblasts, osteoclasts, stromal cells, monocytes-macrophages, and chondrocytes. CaR 
promotes osteoblast proliferation, differentiation and mineralization (Sharan et al.,  2008). It 
also mediates osteoclast differentiation and apoptosis. Therefore, CaR in bone cells 
promotes the bone formation phase of bone remodeling (Yamaguchi, 2008). CaR is also 
expressed in some cancer cells, such as breast and prostate cancers (Liao et al., 2006). 
However, in these cells, increased extracellular calcium leads to increased PTHrP expression 
(Chattopadhyay, 2006). Increased PTHrP induces osteoclastic bone resorption and renal 
calcium reabsorption, resulting in HHM. The positive feedback loop formed by PTHrP, 
calcium and CaR is a unique phenomena in HHM. In addition to the specific activation of 
PTHrP expression, gain-of-function mutations in CaR have been demonstrated in breast 
cancer. Lorch et al. have found single nucleotide polymorphisms in CaR in human lung 
squamous cell carcinoma (Lorch et al.,  2011). Functional evaluation of a nonconservative 
amino acid substitution (R990G) in CaR induced HHM in patients with lung squamous cell 
carcinoma. Dysregulation of PTHrP expression and HHM caused by CaR signaling has been 
demonstrated in breast and prostate cancer (Saidak et al.,  2009). However, the role of CaR in 
HHM induced by lymphoma/leukemia remains to be determined.   
3.7 Role of T cells in calcium homeostasis 
The skeletal and immune systems share many regulatory molecules and systems. An 
interdisciplinary research area called “Osteoimmunology” has been developed recently to 
understand the interplay between these two systems. Cytokines, receptors, signaling 
molecules and transcriptional factors, and their signaling pathways are comprehensively 
reviewed by Takayanagi (Takayanagi, 2007). T-cells have both pro- and antiresorptive 
effects on osteoclasts. The proresorptive effect is present in osteoclast-stimulating T-cells, 
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which secrete a soluble form of RANKL. TNF-ǂ is also expressed by activated T-cells to act 
in concert with RANKL. IL-1, IL-6 and IL-17 secreted from T-cells increase RANKL 
expression in osteoblasts. This mechanism is important for rheumatoid arthritis where TH17 
cells have been shown to be an immunomodulator of osteoclastic bone resorption (Sato et 
al.,  2006). In addition, T-cells produce IL-7 which increase bone resorption in a RANKL-
independent mechanism (Weitzmann & Pacifici, 2005). T-cells also play a major role in 
postmenopausal osteoporosis induced by decreased estrogen levels and decreased 
transforming growth factor (TGF)-ǃ expression in bone cells (Gillespie, 2007).   
In contrast, T-cells can also exert an antiresorptive effect directly by secreting OPG, IL-3, IL-
4, IL-10, IL-13, IFN-ǃ, IFN-Ǆ, GM-CSF, and secreted frizzled-related proteins (sFRPs) to 
inhibit osteoclastogenesis (Quinn & Gillespie, 2005). In addition, T-cells can inhibit 
osteoclast formation and activity indirectly by expressing GM-CSF (induced by the 
upregulation of IL-18 in bone microenvironment), IFN-Ǆ (by IL-12) and OPG (by leptin) 
(Horwood et al.,  2001). It will be important to understand the effects of T-cells on osteoblast 
and stromal cell function, as well as signaling in the immune response to further understand 
the interactions between the immune system and bone biology. 
4. HHM in leukemia/lymphoma in humans and animals 
4.1 Adult T-cell leukemia lymphoma (ATLL) 
50-90% of ATLL patients develop HHM and osteolytic lesions in the long bones and calvaria 
(Olivo et al.,  2008). Bone resorption may act as a ‘vicious cycle’ for ATLL growth in bone, 
since factors released by resorbing bone increased the growth of ATLL and HTLV-1-infected 
T-cells in vitro (Shu et al.,  2010). The mechanisms by which HTLV-1 induces HHM are not 
completely known. We and others have demonstrated that ATLL primary cell lines (T-cell 
lines derived from leukemic ATLL patients) and in vitro HTLV-1 transformed T-cell lines 
express and secrete PTHrP, particularly transcripts from the P3 promoter (Nadella et al.,  
2007; Richard et al.,  2005; Shu et al.,  2010) (Figure 1). The expression of PTHrP was 
upregulated by both oncoviral protein Tax-dependent and -independent pathways. Tax 
cooperates with Ets to activate the P3 promoter of PTHrP, while constitutive activation of 
NF-κB in ATLL cells contributes to expression of the PTHrP P2 promoter (Nadella et al.,  
2007; Richard et al.,  2005). Despite the essential role of PTHrP in HHM in carcinomas (such 
as lung, breast and prostate cancers), the correlation between the plasma PTHrP and HHM 
in ATLL patients has been controversial. It has been concluded that PTHrP is not the sole 
factor that induces HHM in ATLL, but it likely plays an important cooperative or synergistic 
role with other humoral factors (Figure 1). 
In ATLL, there were increased plasma MIP-1ǂ concentrations in mice with human ATLL 
cells and HHM (Shu et al.,  2007). In a human clinical study, plasma MIP-1ǂ concentrations 
had a strong correlation with HHM in ATLL patients (Okada et al.,  2004). MIP-1ǂ 
expression in ATLL cells is induced by Tax and increased plasma calcium concentrations 
may further up-regulate MIP-1ǂ expression through the calmodulin-dependent protein 
kinase kinase (CaM-KK) cascade (Matsumoto et al.,  2008; Sharma & May, 1999). Treatment 
with a neutralizing MIP-1ǂ antibody decreased osteoclast formation induced by ATLL cells 
in vitro (Okada et al.,  2004).   
The increase in RANKL expression observed in the ATL leukemic cells has been shown to 
correlate with the occurrence of HHM in ATLL patients (Nosaka et al.,  2002). Although the 
levels of RANKL expression were not high in HTLV-1-infected cell lines in vitro (Shu et al.,  
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2010), leukemic cells isolated from ATLL patients did have up-regulation of RANKL 
expression (Nosaka et al.,  2002). In addition, HTLV-1 infected leukocytes in vitro were able 
to convert 25-dihydroxyvitamin D3 to its active form, 1ǂ,25-dihydroxyvitamin D3 or calcitriol 
(Fetchick et al.,  1986). High levels of calcitriol have been found in ATLL patients with 
hypercalcemia (Johnston & Hammond, 1992; Seymour & Gagel, 1993) 
 
 
Fig. 1. HHM in ATLL is caused by increased osteoclastic bone resorption. Cancer cells 
secrete bone regulatory factors, including PTHrP, MIP-1, calcitriol, and RANKL to increase 
osteoclast activity. The resorbing bone secretes bone-derived growth factors that increase 
ATLL cell growth. In osteoblasts, the RANKL/OPG expression ratio increases when cells 
are co-cultured with T-cell leukemia lines. Antibodies against HTLV-1 Gp46 can inhibit 
OPG and contributes to the pathogenesis of hypercalcemia. 
In addition to the direct effects of factors secreted from ATLL cells on osteoclasts, we 
recently found decreased OPG expression and secretion in osteoblasts that were co-cultured 
with leukemic T-cell lines (Shu et al.,  2010). This suggests that the regulation of gene 
expression in osteoblasts by leukemic T-cells plays an indirect role in HHM in ATLL.  
Finally, an endogenous antibody recognizing the HTLV-1 viral envelope protein Gp46-197 
can occur in ATLL patients, which correlated with disease progression. The amino acid 
sequence of Gp46-197 is homologous with the C-terminus of OPG. Rabbits immunized 
with the Gp46-197 peptide developed hypercalcemia and died. Sprague-Dawley rats 
injected with Gp46-197 peptide developed decreased bone mineral density and 
hypercalcemia. Administration of recombinant human OPG restored femoral bone 
growth. These data suggest that HTLV-1 Gp46 contributes to the pathogenesis of 
hypercalcemia due to cross-reactive antibodies in the patients that antagonize the action 
of OPG (Sagara et al.,  2009).  
Other factors proposed to be humoral factors for HHM in ATLL include TNF-ǃ 
(lymphotoxin) (Ishibashi et al.,  1992), IL-6 (Chiba et al.,  2009), and IL-1 (Wano et al.,  1987). 
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4.2 Other leukemias/lymphomas that develop HHM (Table 2) 
4.2.1 De novo acute nonlymphocytic leukemia (ANLL)  
Hypercalcemia in de novo ANLL patients can be caused by either local osteolytic 
hypercalcemia or HHM. Elevated circulating concentrations of several humoral factors, 
including PTHrP, TNF-ǂ, IL-6, and M-CSF, in de novo ANLL patients with HHM have been 
reported supporting a role for HHM in ANLL (Kounami et al.,  2004). Generalized 
osteoporosis with normal renal function was observed in these patients, indicating that the 
increased calcium was mainly from bone. 
 
Cancer Type Incidence of HHM Humoral factor(s) 
ATLL 50-90% 
PTHrP, MIP-1ǂ, RANKL, IL-1, 
TNF-ǃ, IL-6 
Diffuse large B cell 
lymphoma 
Rare 
PTHrP, IL-6, 1,25-
dihydroxyvitamin D 
Acute nonlymphocytic 
leukemia 
Rare PTHrP, IL-6, TNF-ǂ, M-CSF 
Primary cutaneous B-
cell lymphoma 
Rare 1,25-dihydroxyvitamin D 
Canine T-cell 
lymphoma 
40% in mediastinal 
lymphoma; 10-20% in 
multicentric lymphoma 
PTHrP, 1,25-dihydroxyvitamin D 
Feline lymphoma Has been reported PTHrP 
Feline leukemia virus 
associated 
leukemia/lymphoma 
Has been reported Unknown 
Avain malignant 
lymphoma 
Has been reported Unknown 
Table 2. Incidence and humoral factors of HHM in leukemia/lymphoma in humans and 
animals. Other undefined factors or cytokines may also be involved.  
4.2.2 Diffuse large B-cell lymphoma 
Increased PTHrP, IL-6, and 1,25-dihydroxyvitamin D concentrations have been reported in 
the serum from patients with diffuse large B cell lymphoma that developed hypercalcemia 
(Amezyane et al.,  2008; Chang et al.,  2008). Diffuse osteolytic lesions and nephrocalcinosis 
also occurred in these patients. 
4.2.3 Primary cutaneous B-cell lymphoma 
Hypercalcemia has been reported in patients with primary cutaneous B-cell lymphoma 
(Habra et al.,  2007; Narimatsu et al.,  2003). Increased serum 1,25-dihydroxyvitamin D and 
undetectable PTH and PTHrP levels were found in one patient. The pathogenesis of 
hypercalcemia in these patients has not been determined. 
4.2.4 HHM in animals with leukemia/lymphoma 
HHM occurs in 10-40% of dogs with T-cell lymphoma (Fournel-Fleury et al.,  2002). 
Increased circulating PTHrP and 1,25-dihydroxyvitamin D were found in dogs with 
lymphoma and HHM, but the serum concentrations did not always correlate with 
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hypercalcemia. Therefore, it was speculated that additional cytokines are involved in the 
pathogenesis of HHM in dogs with lymphoma (Mellanby et al.,  2006; Rosol et al.,  1992). In 
a xenograft mouse model of canine lymphoma, there was increased expression of TNF-ǂ in 
the tumor in vivo (Nadella et al.,  2008). Bone histomorphometry indicated that increased 
osteoclastic bone resorption was the major cause of HHM in these mice. Increased 
circulating PTHrP has also been reported in cats with lymphoma and HHM (Bolliger et al.,  
2002). Cats may also develop HHM due to unknown humoral factors induced by feline 
leukemia virus infection (Engelman et al.,  1985). Hypercalcemia has also been reported in 
an Amazon parrot with lymphoma (de Wit et al.,  2003).  
5. Therapy of HHM in leukemia/lymphoma 
For urgent care, saline hydration is the first step to correct hypercalcemia by diluting the 
serum calcium concentration and increasing the clearance of calcium by the kidneys. 
Treatment of the underlying leukemia/lymphoma, including chemotherapy and radiation 
therapy, is necessary. Several drugs have been used for long-term management of 
hypercalcemia associated with HHM.  
5.1 Bisphosphonates 
Bisphosphonates are structural analogs of pyrophosphoric acid and have been widely used to 
treat cancer patients with hypercalcemia, heritable skeletal disorders in children, and 
postmenopausal and glucocorticoid-induced osteoporosis patients with significant bone loss 
(Fleisch, 1997). Intravenous aminobisphosphonates are a standard of care for the treatment of 
HHM. The newest generation of bisphosphonates, nitrogen-containing aminobisphosphonates, 
inhibits farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) synthetases 
in the mevalonic acid metabolic pathway resulting in decreased prenylation of low-molecular-
weight G proteins including Ras. Functional Ras signaling is necessary for osteoclast activity 
and survival (Fleisch, 1998). It also has been suggested that bisphosphonates exert a cytotoxic 
effect on HTLV-1-infected T-cells. However, high doses of bisphosphonates were needed for 
cytotoxic effects in vitro and in vivo (Gao et al, 2005; Ishikawa et al.,  2007; Shu et al., 2007; Hirbe 
et al., 2009). The clinical relevance of a direct effect of bisphosphonates on ATLL cells needs to 
be further evaluated. Bisphosphonates have a high affinity for bone mineral and bind to 
hydroxyapatite crystals in vivo. Therefore, bisphosphonates are rapidly depleted from the 
circulation and extracellular fluid and become highly concentrated in bone. Bisphosphonate 
therapy may have complications including hypocalcemia, osteonecrosis of the jaw, low bone 
turnover with pathologic fractures, and increased incidence of atrial fibrillation (Drake et al.,  
2008). In addition to the effects on osteoclasts, a new bisphosphonate, YM527/ONO-5920, 
decreased MIP-1ǂ expression and secretion through inhibition of the transient increase of 
phosphorylated ERK1/2 and Akt in mouse myeloma cells after lipopolysaccharide (LPS) 
stimulation (Drake & Rajkumar, 2009). Since MIP-1ǂ has been shown to play an important role 
in cancer cell growth and osteolysis in multiple myeloma, bisphosphonates may be useful for 
inhibiting the growth of myeloma cells and to prevent osteolysis by decreasing MIP-1ǂ 
expression. This may also apply to ATLL. Commonly used bisphosphonates include 
pamidronate and zoledronic acid.  
5.2 Calcitonin 
Calcitonin is a 32-amino acid peptide secreted by thyroid C-cells. It inhibits calcium 
absorption in the intestine and reabsorption of calcium and phosphate in renal tubules. It is 
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a potent (but transient) inhibitor of osteoclastic bone resorption. The mechanisms of action 
have been shown to involve several signaling pathways including cAMP/PKA, PKC, and 
pyk2/src activity. It has also been shown that calcitonin up-regulates renal 1ǂ-hydroxylase, 
an important enzyme for the synthesis of calcitriol, through the binding of C/EBPǃ and 
brahma-related gene 1 (BRG1), an ATPase in the SWItch/Sucrose NonFermentable 
(SWI/SNF) chromatin remodeling complex, on the 1ǂ-hydroxylase promoter (Zhong et al.,  
2009). Because of its potent inhibitory effect on bone resorption, calcitonin has clinical 
applications in the treatment of Paget’s disease, osteoporosis, and hypercalcemia. However, 
due to its short duration of action, calcitonin may not be suitable for treatment of chronic 
hypercalcemia. Salmon calcitonin is used clinically due to its greater potency compared to 
human calcitonin (Zaidi et al.,  2002). 
5.3 Corticosteroids 
Corticosteroids have been used for the treatment of hypercalcemia induced by multiple 
myeloma and certain types of lymphoma. Corticosteroids act by decreasing calcium 
absorption in gastrointestinal tract, decreasing bone resorption, and increasing renal calcium 
excretion (Unal et al.,  2008; Yarbro et al.,  2003). Corticosteroids generally are not effective in 
patients with HHM induced by solid tumors.   
5.4 Bortezomib (PS-341)  
Bortezomib is a selective proteasome inhibitor that decreases the ubiquination of IκB, the 
inhibitor for NF-κB, thereby stabilizing IκB and inhibiting NF-κB. NF-κB is necessary for 
osteoclast function and constitutively activated NF-κB plays an important role in ATLL cells. 
Bortezomib has been shown to inhibit tumor growth in models of ATLL (Mitra-Kaushik et 
al.,  2004b; Nasr et al.,  2005; Satou et al.,  2004; Shu et al.,  2007; Tan & Waldmann, 2002). 
Shu et al. reported that bortezomib not only decreased tumor burden in mice bearing ATLL 
cells, but also decreased the severity of HHM (Shu et al.,  2007). Although the decrease in 
serum calcium concentrations was mainly due to the decreased tumor burden, several 
studies have shown that bortezomib inhibited osteoclastogenesis by decreasing p38, AP-1 
and NF-κB activity in osteoclasts (von Metzler et al.,  2007) and increased bone formation by 
decreasing the expression of Dkk-1, a potent osteoblast inhibitor (Drake & Rajkumar, 2009; 
Heider et al.,  2009; Pennisi et al.,  2009; Qiang et al.,  2009; Terpos et al.,  2006). Bortezomib is 
now a standard of care for treatment of multiple myeloma patients. Several clinical trials 
involving bortezomib are ongoing for the treatment of prostate cancer, nonsmall cell lung 
cancer, acute myelogenous leukemia, and other cancers.  
5.5 Humanized anti-parathyroid hormone-related protein antibody and small molecule 
antagonists of the PTH/PTHrP receptor (PTH1R) 
Although bisphophonates have been widely used for treatment of HHM to inhibit 
osteoclastic bone resorption, they do not function on the kidney to decrease renal calcium 
reabsorption. To eliminate the actions of PTHrP in bone and kidney, an anti-PTHrP 
antibody has been developed and tested (Sato et al.,  2003). Anti-PTHrP antibody prevented 
hypercalcemia and skeletal metastasis, but not visceral metastasis, induced by PTHrP-
producing cancer cells in mice (Guise & Mundy, 1996; Sato et al.,  2003). Although it has 
been difficult to identify small molecule antagonists for type B G-protein-coupled receptors, 
including the PTH1R, two compounds have been recently developed that antagonize 
PTH1R. SW106 was discovered by Bristol-Myers-Squibb Company by screening compounds 
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that inhibited targets downstream of the PTHR1 (Carter et al.,  2007). The benzoxazepinone 
non-peptide inhibits the cAMP response induced by a PTH1R agonist. The pharmacological 
behavior of SW106 is not yet completely understood. A similar compound, 1,3,4-
benzotriazepine was identified and serves as a base molecule to develop non-peptide 
PTH1R antagonist derivatives (McDonald et al.,  2007). Using a radioligand binding assay 
that measures cAMP production, N-1 anilino-substituted compounds were identified that 
have up to a 1000-fold more potency at inhibiting PTH1R compared to the original 
compound. Efforts are ongoing to determine the effects of these compounds on bone 
metastasis, hypercalcemia and hyperparathyroidism.  
5.6 RANKL inhibitors  
Ever since RANKL and OPG were discovered to be major regulators of osteoclastic bone 
resorption, RANK-Fc, Fc-OPG, antibodies targeting RANKL or inhibitors imitating OPG 
function have been developed for the treatment of osteolytic bone diseases (Schwarz & 
Ritchlin, 2007). RANK-Fc was generated by combining the carboxyl-terminus of RANK with 
the Fc portion of human IgG1. It has been shown to decrease tumor burden in two multiple 
myeloma mouse models, inhibit prostate cancer bone metastasis, and decrease the incidence 
of lung metastasis and bone lysis in a osteosarcoma mouse model (Lamoureux et al.,  2008; 
Sordillo & Pearse, 2003; Zhang et al.,  2003). Fc-OPG was generated by combining the Fc 
portion of the immunoglobulin heavy chain to the amino-terminus of OPG. The inhibitory 
effect of Fc-OPG on bone resorption is similar to pamidronate (Bekker et al.,  2001; Body et 
al.,  2003). However, Fc-OPG and RANK-Fc  have been replaced by denosumab (Amgen), 
which is a fully human monoclonal antibody developed using the xenomouse technology 
that specifically inhibits primate RANKL (Green, 1999). Denosumab does not bind to 
murine RANKL, human TRAIL, or other TNF family proteins and has a longer half-life than 
Fc-OPG (Kostenuik et al.,  2009). Denosumab has been tested in patients with varying 
diseases/conditions, including osteoporosis, treatment-induced bone loss, bone metastases, 
multiple myeloma and rheumatoid arthritis, and is now a standard of care for patients with 
solid tumor bone metastases (Schwarz & Ritchlin, 2007). Denosumab can significantly delay 
or prevent skeleton-related events (SREs), including hypercalcemia, in patients with bone 
metastasis (Castellano et al.,  2011).  Due to its longer half life, higher specificity and lower 
toxicity, the therapeutic potential of denosumab is superior to that of Fc-OPG and RANK-Fc 
(Schwarz & Ritchlin, 2007).    
6. Development of in vivo models of HHM in leukemia/lymphoma 
6.1 Mouse models of HHM and ATLL 
Animal models of ATLL are divided into infectious models, which are useful to study viral 
infection, viral transmission and the immune response, and pathogenesis models, which are 
useful for preclinical therapy studies. Pathogenesis models, including tumor xenografts and 
transgenic mice that develop tumors, are useful to study the development and treatment of 
HHM in ATLL. Unfortunately, there are few animal models of ATLL that develop HHM. 
The following animal models are currently available for studying HHM in ATLL.  
6.1.1 Human RV-ATL xenograft mouse model of ATLL 
The RV-ATL model was first developed by the laboratory of Dr. Irvin Chen by injecting RV-
ATL cells, derived from an ATLL patient, into severe combined immunodeficient (SCID) 
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mice (Feuer et al.,  1993). Richard et al. characterized the tumorigenesis and HHM of this cell 
line in SCID/beige mice (Richard et al.,  2001). SCID/beige mice developed severe 
hypercalcemia one month after intraperitoneal injection of RV-ATL cells. The mice had bone 
loss due to increased osteoclastic bone resorption. Shu et al. introduced the luciferase gene 
into the RV-ATL cells by lentiviral infection and developed a bioluminescent model of 
HHM in ATLL for preclinical studies (Shu et al.,  2007). It was found that both zoledronic 
acid, a nitrogen-containing bisphosphonate, and PS-341, a selective proteasome inhibitor, 
decreased tumor burden and HHM in mice. No complication of using the combination of 
PS-341 and zoledronic acid was observed in this preclinical study (Shu et al.,  2007). 
6.1.2 Uchiyama human xenograft mouse model of ATLL 
The laboratory of Dr. Takashi Uchiyama developed a mouse xenograft model by injecting 
cells from the lymph node of a lymphoma-type ATLL patient intraperitoneally into SCID 
mice (Imada et al.,  1996). The mice developed tumors and hypercalcemia within three 
weeks. There was a marked increase in serum C-terminal PTHrP concentrations with 
decreased bone formation rates reported in the mice (Takaori-Kondo et al.,  1998). However, 
no significant increase in bone resorption measured by bone histomorphometry was 
observed in the mice, which is in contrast to ATLL patients with HHM.  
6.1.3 Human MET-1 xenograft mouse model of ATLL 
Recently, a NOD/SCID mouse model using human ATLL MET-1 cells has been developed 
(Phillips et al.,  2000). The mice developed leukemia and HHM after intraperitoneal 
injection. Marked infiltration of tumor cells in multiple organs including spleen, lungs, liver, 
lymph nodes was observed. Increased plasma PTHrP concentrations in the mice and 
expression of PTHrP and RANKL in MET-1 cells were reported (Parrula et al.,  2009). It is 
not known whether the HHM in this model was caused by an increase in bone resorption or 
other mechanisms.  
6.1.4 HTLV-1 LTR-Tax transgenic model 
Transgenic mice have been used to study the pathogenesis and role of the HTLV-1 viral 
oncoprotein, Tax. Several Tax transgenic mice have been developed using different 
promoters. A transgenic mouse model overexpressing Tax under the regulation of the 
HTLV-1 long terminal repeat (LTR) was generated (Ruddle et al.,  1993). These mice 
developed neurofibromas and adrenal medullary tumors, but did not develop leukemia or 
lymphoma. Unexpectedly, a significant increase in bone remodeling with a net increase in 
bone volume was observed. This was surprising because the authors also demonstrated that 
osteoclasts were increased in number, size and degree of multinucleation, which would 
have been expected to lead to a net decrease in bone volume. It was not reported whether 
HHM developed in the mice.  
6.1.5 Human granzyme B-Tax transgenic mice 
The laboratory of Dr. Lee Ratner developed a tissue-specific Tax overexpressing mouse model 
(Grossman et al.,  1995). Tax expression in the mice was under the regulation of the human 
granzyme B promoter, which limited Tax expression primarily to activated CD4+ and CD8+ T-
cells and NK cells. The mice developed mild hypercalcemia and multifocal osteolytic bone 
lesions, especially in the tail, with increased osteoclastic bone resorption (Gao et al.,  2005). The 
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mice have increased serum IL-6 concentrations, which is a potent osteoclast activator. When 
the mice were crossed to mice that overexpressed OPG, they were protected from the 
development of osteolytic lesions and soft tissue tumors, indicating that increased bone 
resorption in Tax transgenic mice was induced, at least in part, through a RANKL-dependent 
pathway. The mouse model also has been used for preclinical studies and zoledronic acid not 
only prevented the osteolytic bone lesions but also decreased tumor burden. After crossing the 
mice with IFN-Ǆ knockout mice, the resulting Tax+IFN-Ǆ-/- mice had accelerated tumor 
formation, dissemination, and death, when compared with Tax+IFN-Ǆ+/- or Tax+IFN-Ǆ+/+ mice 
(Mitra-Kaushik et al.,  2004a). The mice also develop increased osteolytic bone lesions, 
increased osteoclast formation and more severe hypercalcemia compared to Tax+IFN-Ǆ+/+ mice 
(Xu et al.,  2009). These data indicate that IFN-Ǆ may contribute to the host defense systems 
that prevent HTLV-1-induced malignancy, bone metastasis and HHM. 
6.2 Mouse model of canine lymphoma and HHM 
A bioluminescent NOD/SCID mouse model of canine T-cell lymphoma and HHM has been 
developed (Nadella et al.,  2008). The mice developed multicentric lymphoma in the 
mesenteric lymph nodes after intraperitoneal injection of tumor cells. Moderate to marked 
splenomegaly and enlarged thymuses were observed. There was increased osteoclastic bone 
resorption in trabecular bone in mice with lymphoma. HHM developed 6-8 weeks after 
injection of tumor cells. The increase in plasma PTHrP concentrations likely played a central 
role in HHM in the mice. The cause of canine T-cell lymphoma is unknown and retroviruses 
have not been identified as a cause of lymphoma in dogs (in contrast to humans and cats).  
7. Conclusion 
HHM is a life-threatening complication in certain patients with lymphoma or leukemia. As 
outlined in this review, progress has been made in elucidating the mechanisms by which 
humoral factors from neoplastic lymphocytes induce HHM, including increased osteoclastic 
bone resorption and renal calcium reabsorption. However, further efforts are needed to fully 
understand the pathogenesis of HHM, including the endocrine or paracrine role of 
interactions between tumor-associated and host-produced cytokines. PTHrP plays a major 
endocrine and paracrine role in HHM, but the effects of other factors secreted from tumor 
cells or host cells cannot be neglected. For example, the expression of RANKL in ATLL cells 
suggests that ATLL cells may function directly as inducers of osteoclastic bone resorption. 
Additional effective treatments are needed for this paraneoplastic syndrome. Small 
molecules or humanized antibodies targeting essential factors or their receptors may be an 
attractive future therapeutic strategy for treatment of HHM. 
8. Acknowledgements 
This work was supported by the National Cancer Institute (P01 CA100730) and the National 
Center for Research Resources (T32 RR07073). We thank Tim Vojt for the illustrations. 
9. References 
Abu-Amer, Y.; Ross, F. P.; Edwards, J. & Teitelbaum, S. L. (1997). Lipopolysaccharide-
stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 
receptor. J.Clin.Invest, 100, No.6, pp. 1557-1565, 0021-9738 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
195 
Abu-Amer, Y.; Ross, F. P.; McHugh, K. P.; Livolsi, A.; Peyron, J. F. & Teitelbaum, S. L. (1998). 
Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in 
marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa 
Balpha. J.Biol.Chem., 273, No.45, pp. 29417-29423, 0021-9258 
Amezyane, T.; Lecoules, S.; Bordier, L.; Blade, J. S.; Desrame, J.; Bechade, D.; Coutant, G. & 
Algayres, J. P. (2008). [Humoral hypercalcemia revealing a malignant non hodgkin 
lymphoma]. Ann.Endocrinol.(Paris), 69, No.1, pp. 58-62, 0003-4266 
Asanuma, N.; Hagiwara, K.; Matsumoto, I.; Matsuda, M.; Nakamura, F.; Kouhara, H.; 
Miyamoto, M.; Miyashita, Y.; Noguchi, S. & Morimoto, Y. (2002). PTHrP-producing 
tumor: squamous cell carcinoma of the liver accompanied by humoral 
hypercalcemia of malignancy, increased IL-6 and leukocytosis. Intern.Med., 41, 
No.5, pp. 371-376, 0918-2918 
Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; 
Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K. & Fujino, M. (1999). A small-
molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 
activity. Proc.Natl.Acad.Sci.U.S.A, 96, No.10, pp. 5698-5703, 0027-8424 
Bekker, P. J.; Holloway, D.; Nakanishi, A.; Arrighi, M.; Leese, P. T. & Dunstan, C. R. (2001). 
The effect of a single dose of osteoprotegerin in postmenopausal women. J.Bone 
Miner.Res., 16, No.2, pp. 348-360, 0884-0431 
Body, J. J.; Greipp, P.; Coleman, R. E.; Facon, T.; Geurs, F.; Fermand, J. P.; Harousseau, J. L.; 
Lipton, A.; Mariette, X.; Williams, C. D.; Nakanishi, A.; Holloway, D.; Martin, S. W.; 
Dunstan, C. R. & Bekker, P. J. (2003). A phase I study of AMGN-0007, a 
recombinant osteoprotegerin construct, in patients with multiple myeloma or 
breast carcinoma related bone metastases. Cancer, 97, No.3 Suppl, pp. 887-892, 
0008-543X 
Bolliger, A. P.; Graham, P. A.; Richard, V.; Rosol, T. J.; Nachreiner, R. F. & Refsal, K. R. 
(2002). Detection of parathyroid hormone-related protein in cats with humoral 
hypercalcemia of malignancy. Vet.Clin.Pathol., 31, No.1, pp. 3-8, 0275-6382 
Broadus, A. E.; Mangin, M.; Ikeda, K.; Insogna, K. L.; Weir, E. C.; Burtis, W. J. & Stewart, A. 
F. (1988). Humoral hypercalcemia of cancer. Identification of a novel parathyroid 
hormone-like peptide. N.Engl.J.Med., 319, No.9, pp. 556-563, 0028-4793 
Bucay, N.; Sarosi, I.; Dunstan, C. R.; Morony, S.; Tarpley, J.; Capparelli, C.; Scully, S.; Tan, H. 
L.; Xu, W.; Lacey, D. L.; Boyle, W. J. & Simonet, W. S. (1998). Osteoprotegerin-
deficient mice develop early onset osteoporosis and arterial calcification. Genes 
Dev., 12, No.9, pp. 1260-1268, 0890-9369 
Carter, P. H.; Liu, R. Q.; Foster, W. R.; Tamasi, J. A.; Tebben, A. J.; Favata, M.; Staal, A.; 
Cvijic, M. E.; French, M. H.; Dell, V.; Apanovitch, D.; Lei, M.; Zhao, Q.; 
Cunningham, M.; Decicco, C. P.; Trzaskos, J. M. & Feyen, J. H. (2007). Discovery of 
a small molecule antagonist of the parathyroid hormone receptor by using an N-
terminal parathyroid hormone peptide probe. Proc.Natl.Acad.Sci.U.S.A, 104, No.16, 
pp. 6846-6851, 0027-8424 
Castellano, D.; Sepulveda, J. M.; Garcia-Escobar, I.; Rodriguez-Antolin, A.; Sundlov, A. & 
Cortes-Funes, H. (2011). The role of RANK-ligand inhibition in cancer: the story of 
denosumab. Oncologist., 16, No.2, pp. 136-145, 1083-7159 
www.intechopen.com
 
T-Cell Leukemia 
 
196 
Chang, P. Y.; Lee, S. H.; Chao, T. K. & Chao, T. Y. (2008). Acute renal failure due to 
hypercalcemia-related nephrocalcinosis in a patient of non-Hodgkin's lymphoma 
featuring swelling of bilateral kidneys. Ann.Hematol., 87, No.6, pp. 489-490, 0939-
5555 
Chattopadhyay, N. (2006). Effects of calcium-sensing receptor on the secretion of 
parathyroid hormone-related peptide and its impact on humoral hypercalcemia of 
malignancy. Am.J.Physiol Endocrinol.Metab, 290, No.5, p. E761-E770, 0193-1849 
Chiba, K.; Hashino, S.; Izumiyama, K.; Toyoshima, N.; Suzuki, S.; Kurosawa, M. & Asaka, 
M. (2009). Multiple osteolytic bone lesions with high serum levels of interleukin-6 
and CCL chemokines in a patient with adult T cell leukemia. Int.J.Lab Hematol., 31, 
No.3, pp. 368-371, 1751-5521 
Choi, S. J.; Cruz, J. C.; Craig, F.; Chung, H.; Devlin, R. D.; Roodman, G. D. & Alsina, M. 
(2000). Macrophage inflammatory protein 1-alpha is a potential osteoclast 
stimulatory factor in multiple myeloma. Blood, 96, No.2, pp. 671-675, 0006-4971 
Chu, C. Q.; Field, M.; Feldmann, M. & Maini, R. N. (1991). Localization of tumor necrosis 
factor alpha in synovial tissues and at the cartilage-pannus junction in patients with 
rheumatoid arthritis. Arthritis Rheum., 34, No.9, pp. 1125-1132, 0004-3591 
de Gortazar, A. R.; Alonso, V.; Alvarez-Arroyo, M. V. & Esbrit, P. (2006). Transient exposure 
to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth 
factor receptor 2 in human osteoblastic cells in vitro. Calcif.Tissue Int., 79, No.5, pp. 
360-369, 0171-967X 
de Wit, M.; Schoemaker, N. J.; Kik, M. J. & Westerhof, I. (2003). Hypercalcemia in two 
Amazon parrots with malignant lymphoma. Avian Dis., 47, No.1, pp. 223-228, 
0005-2086 
Drake, M. T.; Clarke, B. L. & Khosla, S. (2008). Bisphosphonates: mechanism of action and 
role in clinical practice. Mayo Clin.Proc., 83, No.9, pp. 1032-1045, 0025-6196 
Drake, M. T. & Rajkumar, S. V. (2009). Effects of bortezomib on bone disease in multiple 
myeloma. Am.J.Hematol., 84, No.1, pp. 1-2, 0361-8609 
Ejima, E.; Rosenblatt, J. D.; Massari, M.; Quan, E.; Stephens, D.; Rosen, C. A. & Prager, D. 
(1993). Cell-type-specific transactivation of the parathyroid hormone-related 
protein gene promoter by the human T-cell leukemia virus type I (HTLV-I) tax and 
HTLV-II tax proteins. Blood, 81, No.4, pp. 1017-1024, 0006-4971 
Engelman, R. W.; Tyler, R. D.; Good, R. A. & Day, N. K. (1985). Hypercalcemia in cats with 
feline-leukemia-virus-associated leukemia-lymphoma. Cancer, 56, No.4, pp. 777-
781, 0008-543X 
Ferrajoli, A.; Keating, M. J.; Manshouri, T.; Giles, F. J.; Dey, A.; Estrov, Z.; Koller, C. A.; 
Kurzrock, R.; Thomas, D. A.; Faderl, S.; Lerner, S.; O'Brien, S. & Albitar, M. (2002). 
The clinical significance of tumor necrosis factor-alpha plasma level in patients 
having chronic lymphocytic leukemia. Blood, 100, No.4, pp. 1215-1219, 0006-4971 
Fetchick, D. A.; Bertolini, D. R.; Sarin, P. S.; Weintraub, S. T.; Mundy, G. R. & Dunn, J. F. 
(1986). Production of 1,25-dihydroxyvitamin D3 by human T cell lymphotrophic 
virus-I-transformed lymphocytes. J.Clin.Invest, 78, No.2, pp. 592-596, 0021-9738 
Feuer, G.; Zack, J. A.; Harrington, W. J., Jr.; Valderama, R.; Rosenblatt, J. D.; Wachsman, W.; 
Baird, S. M. & Chen, I. S. (1993). Establishment of human T-cell leukemia virus type 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
197 
I T-cell lymphomas in severe combined immunodeficient mice. Blood, 82, No.3, pp. 
722-731, 0006-4971 
Fleisch, H. (1997). Mechanisms of action of the bisphosphonates. Medicina (B Aires), 57 
Suppl 1, pp. 65-75, 0025-7680 
Fleisch, H. (1998). Bisphosphonates: mechanisms of action. Endocr.Rev., 19, No.1, pp. 80-
100, 0163-769X 
Fournel-Fleury, C.; Ponce, F.; Felman, P.; Blavier, A.; Bonnefont, C.; Chabanne, L.; Marchal, 
T.; Cadore, J. L.; Goy-Thollot, I.; Ledieu, D.; Ghernati, I. & Magnol, J. P. (2002). 
Canine T-cell lymphomas: a morphological, immunological, and clinical study of 46 
new cases. Vet.Pathol., 39, No.1, pp. 92-109, 0300-9858 
Fuller, K.; Owens, J. M. & Chambers, T. J. (1995). Macrophage inflammatory protein-1 alpha 
and IL-8 stimulate the motility but suppress the resorption of isolated rat 
osteoclasts. J.Immunol., 154, No.11, pp. 6065-6072, 0022-1767 
Gallo, J.; Raska, M.; Mrazek, F. & Petrek, M. (2008). Bone remodeling, particle disease and 
individual susceptibility to periprosthetic osteolysis. Physiol Res., 57, No.3, pp. 339-
349, 0862-8408 
Gao, L.; Deng, H.; Zhao, H.; Hirbe, A.; Harding, J.; Ratner, L. & Weilbaecher, K. (2005). 
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases 
prevented by osteoclast inhibition. Blood, 106, No.13, pp. 4294-4302, 0006-4971 
Gillespie, M. T. (2007). Impact of cytokines and T lymphocytes upon osteoclast 
differentiation and function. Arthritis Res.Ther., 9, No.2, p. 103, 1478-6354 
Green, L. L. (1999). Antibody engineering via genetic engineering of the mouse: XenoMouse 
strains are a vehicle for the facile generation of therapeutic human monoclonal 
antibodies. J.Immunol.Methods, 231, No.1-2, pp. 11-23, 0022-1759 
Greenfield, E. M.; Shaw, S. M.; Gornik, S. A. & Banks, M. A. (1995). Adenyl cyclase and 
interleukin 6 are downstream effectors of parathyroid hormone resulting in 
stimulation of bone resorption. J.Clin.Invest, 96, No.3, pp. 1238-1244, 0021-9738 
Grossman, W. J.; Kimata, J. T.; Wong, F. H.; Zutter, M.; Ley, T. J. & Ratner, L. (1995). 
Development of leukemia in mice transgenic for the tax gene of human T-cell 
leukemia virus type I. Proc.Natl.Acad.Sci.U.S.A, 92, No.4, pp. 1057-1061, 
0027-8424 
Guise, T. A.; Kozlow, W. M.; Heras-Herzig, A.; Padalecki, S. S.; Yin, J. J. & Chirgwin, J. M. 
(2005). Molecular mechanisms of breast cancer metastases to bone. Clin.Breast 
Cancer, 5 Suppl, No.2, p. S46-S53, 1526-8209 
Guise, T. A. & Mundy, G. R. (1996). Physiological and pathological roles of parathyroid 
hormone-related peptide. Curr.Opin.Nephrol.Hypertens., 5, No.4, pp. 307-315, 
1062-4821 
Habra, M. A.; Weaver, E. J. & Prewitt, P. V., III (2007). Primary cutaneous large B-cell 
lymphoma of the leg and acute hypercalcemia. J.Clin.Oncol., 25, No.36, pp. 5825-
5826, 0732-183X 
Han, J. H.; Choi, S. J.; Kurihara, N.; Koide, M.; Oba, Y. & Roodman, G. D. (2001). 
Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma 
that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97, 
No.11, pp. 3349-3353, 0006-4971 
www.intechopen.com
 
T-Cell Leukemia 
 
198 
Heider, U.; Kaiser, M.; Mieth, M.; Lamottke, B.; Rademacher, J.; Jakob, C.; Braendle, E.; 
Stover, D. & Sezer, O. (2009). Serum concentrations of DKK-1 decrease in patients 
with multiple myeloma responding to anti-myeloma treatment. Eur.J.Haematol., 
82, No.1, pp. 31-38, 0902-4441 
Hewison, M.; Kantorovich, V.; Liker, H. R.; Van Herle, A. J.; Cohan, P.; Zehnder, D. & 
Adams, J. S. (2003). Vitamin D-mediated hypercalcemia in lymphoma: evidence for 
hormone production by tumor-adjacent macrophages. J.Bone Miner.Res., 18, No.3, 
pp. 579-582, 0884-0431 
Hirbe, A.C., Roelofs, A.J., Floyd, D.H., Deng, H., Becker, S.N., Lanigan, L.G., Apicelli, A.J., 
Xu, Z., Prior, J.L., Eagleton, M.C., Piwnica-Worms, D., Rogers, M.J., & Weilbaecher, 
K. (2009). The bisphosphonate zoledronic acid decreases tumor growth in bone in 
mice with defective osteoclasts. Bone, 44, No. 5, pp. 908-916, 8756-3282 
Hofbauer, L. C.; Khosla, S.; Dunstan, C. R.; Lacey, D. L.; Boyle, W. J. & Riggs, B. L. (2000). 
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation 
of bone resorption. J.Bone Miner.Res., 15, No.1, pp. 2-12, 0884-0431 
Horowitz, M. C. (1993). Cytokines and estrogen in bone: anti-osteoporotic effects. Science, 
260, No.5108, pp. 626-627, 0036-8075 
Horwood, N. J.; Elliott, J.; Martin, T. J. & Gillespie, M. T. (1998). Osteotropic agents regulate 
the expression of osteoclast differentiation factor and osteoprotegerin in 
osteoblastic stromal cells. Endocrinology, 139, No.11, pp. 4743-4746, 0013-7227 
Horwood, N. J.; Elliott, J.; Martin, T. J. & Gillespie, M. T. (2001). IL-12 alone and in synergy 
with IL-18 inhibits osteoclast formation in vitro. J.Immunol., 166, No.8, pp. 4915-
4921, 0022-1767 
Hounoki, H.; Sugiyama, E.; Mohamed, S. G.; Shinoda, K.; Taki, H.; Abdel-Aziz, H. O.; 
Maruyama, M.; Kobayashi, M. & Miyahara, T. (2008). Activation of peroxisome 
proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast 
differentiation in human peripheral monocytes in part via suppression of 
monocyte chemoattractant protein-1 expression. Bone, 42, No.4, pp. 765-774, 
8756-3282 
Imada, K.; Takaori-Kondo, A.; Sawada, H.; Imura, A.; Kawamata, S.; Okuma, M. & 
Uchiyama, T. (1996). Serial transplantation of adult T cell leukemia cells into severe 
combined immunodeficient mice. Jpn.J.Cancer Res., 87, No.9, pp. 887-892, 
0910-5050 
Ishibashi, K.; Kodama, M.; Hanada, S. & Arima, T. (1992). Tumor necrosis factor-beta and 
hypercalcemia. Leuk.Lymphoma, 7, No.5-6, pp. 409-417, 1042-8194 
Ishikawa, C.; Matsuda, T.; Okudaira, T.; Tomita, M.; Kawakami, H.; Tanaka, Y.; Masuda, M.; 
Ohshiro, K.; Ohta, T. & Mori, N. (2007). Bisphosphonate incadronate inhibits 
growth of human T-cell leukaemia virus type I-infected T-cell lines and primary 
adult T-cell leukaemia cells by interfering with the mevalonate pathway. 
Br.J.Haematol., 136, No.3, pp. 424-432, 0007-1048 
Johnston, S. R. & Hammond, P. J. (1992). Elevated serum parathyroid hormone related 
protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult 
T-cell leukaemia-lymphoma. Postgrad.Med.J., 68, No.803, pp. 753-755, 0032-5473 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
199 
Karaplis, A. C.; Luz, A.; Glowacki, J.; Bronson, R. T.; Tybulewicz, V. L.; Kronenberg, H. M. & 
Mulligan, R. C. (1994). Lethal skeletal dysplasia from targeted disruption of the 
parathyroid hormone-related peptide gene. Genes Dev., 8, No.3, pp. 277-289, 
0890-9369 
Kostenuik, P. J.; Nguyen, H. Q.; McCabe, J.; Warmington, K. S.; Kurahara, C.; Sun, N.; Chen, 
C.; Li, L.; Cattley, R. C.; Van, G.; Scully, S.; Elliott, R.; Grisanti, M.; Morony, S.; Tan, 
H. L.; Asuncion, F.; Li, X.; Ominsky, M. S.; Stolina, M.; Dwyer, D.; Dougall, W. C.; 
Hawkins, N.; Boyle, W. J.; Simonet, W. S. & Sullivan, J. K. (2009). Denosumab, a 
fully human monoclonal antibody to RANKL, inhibits bone resorption and 
increases BMD in knock-in mice that express chimeric (murine/human) RANKL. 
J.Bone Miner.Res., 24, No.2, pp. 182-195, 0884-0431 
Kounami, S.; Yoshiyama, M.; Nakayama, K.; Hiramatsu, C.; Aoyagi, N. & Yoshikawa, N. 
(2004). Severe hypercalcemia in a child with acute nonlymphocytic leukemia: the 
role of parathyroid hormone-related protein and proinflammatory cytokines. Acta 
Haematol., 112, No.3, pp. 160-163, 0001-5792 
Kudo, O.; Fujikawa, Y.; Itonaga, I.; Sabokbar, A.; Torisu, T. & Athanasou, N. A. (2002). 
Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast 
formation. J.Pathol., 198, No.2, pp. 220-227, 0022-3417 
Lacey, D. L.; Timms, E.; Tan, H. L.; Kelley, M. J.; Dunstan, C. R.; Burgess, T.; Elliott, R.; 
Colombero, A.; Elliott, G.; Scully, S.; Hsu, H.; Sullivan, J.; Hawkins, N.; Davy, E.; 
Capparelli, C.; Eli, A.; Qian, Y. X.; Kaufman, S.; Sarosi, I.; Shalhoub, V.; Senaldi, G.; 
Guo, J.; Delaney, J. & Boyle, W. J. (1998). Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and activation. Cell, 93, No.2, pp. 165-176, 
0092-8674 
Lam, J.; Takeshita, S.; Barker, J. E.; Kanagawa, O.; Ross, F. P. & Teitelbaum, S. L. (2000). TNF-
alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to 
permissive levels of RANK ligand. J.Clin.Invest, 106, No.12, pp. 1481-1488, 
0021-9738 
Lamoureux, F.; Picarda, G.; Rousseau, J.; Gourden, C.; Battaglia, S.; Charrier, C.; Pitard, B.; 
Heymann, D. & Redini, F. (2008). Therapeutic efficacy of soluble receptor 
activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a 
mouse model of osteolytic osteosarcoma. Mol.Cancer Ther., 7, No.10, pp. 3389-
3398, 1535-7163 
Leibbrandt, A. & Penninger, J. M. (2008). RANK/RANKL: regulators of immune responses 
and bone physiology. Ann.N.Y.Acad.Sci., 1143, pp. 123-150, 0077-8923 
Li, J.; Sarosi, I.; Yan, X. Q.; Morony, S.; Capparelli, C.; Tan, H. L.; McCabe, S.; Elliott, R.; 
Scully, S.; Van, G.; Kaufman, S.; Juan, S. C.; Sun, Y.; Tarpley, J.; Martin, L.; 
Christensen, K.; McCabe, J.; Kostenuik, P.; Hsu, H.; Fletcher, F.; Dunstan, C. R.; 
Lacey, D. L. & Boyle, W. J. (2000). RANK is the intrinsic hematopoietic cell surface 
receptor that controls osteoclastogenesis and regulation of bone mass and calcium 
metabolism. Proc.Natl.Acad.Sci.U.S.A, 97, No.4, pp. 1566-1571, 0027-8424 
Liao, J.; Schneider, A., Datta N.S., & McCauley, L.K. (2006). Extracellular calcium as a 
candidate mediator of prostate cancer skeletal metastasis. Cancer Res., 66, No. 18, 
pp. 9065-9073, 0008-5472 
www.intechopen.com
 
T-Cell Leukemia 
 
200 
Lipton, A.; Uzzo, R.; Amato, R. J.; Ellis, G. K.; Hakimian, B.; Roodman, G. D. & Smith, M. R. 
(2009). The science and practice of bone health in oncology: managing bone loss 
and metastasis in patients with solid tumors. J.Natl.Compr.Canc.Netw., 7 Suppl 7, 
pp. S1-29, 1540-1405 
Lomaga, M. A.; Yeh, W. C.; Sarosi, I.; Duncan, G. S.; Furlonger, C.; Ho, A.; Morony, S.; 
Capparelli, C.; Van, G.; Kaufman, S.; van der Heiden, A.; Itie, A.; Wakeham, A.; 
Khoo, W.; Sasaki, T.; Cao, Z.; Penninger, J. M.; Paige, C. J.; Lacey, D. L.; Dunstan, C. 
R.; Boyle, W. J.; Goeddel, D. V. & Mak, T. W. (1999). TRAF6 deficiency results in 
osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev., 13, 
No.8, pp. 1015-1024, 0890-9369 
Lorch, G.; Viatchenko-Karpinski, S.; Ho, H. T.; Dirksen, W. P.; Toribio, R. E.; Foley, J.; 
Györke, S. & Rosol, T. J. (2011). The calcium-sensing receptor is necessary for the 
rapid development of hypercalcemia in human lung squamous cell carcinoma. 
Neoplasia, 13, No.5, pp. 428-438, 1522-8802  
Lu, T. & Stark, G. R. (2004). Cytokine overexpression and constitutive NFkappaB in cancer. 
Cell Cycle, 3, No.9, pp. 1114-1117, 1538-4101 
Matsumoto, K.; Murao, K.; Imachi, H.; Nishiuchi, T.; Cao, W.; Yu, X.; Li, J.; Ahmed, R. A.; 
Iwama, H.; Kobayashi, R.; Tokumitsu, H. & Ishida, T. (2008). The role of 
calcium/calmodulin-dependent protein kinase cascade on MIP-1alpha gene 
expression of ATL cells. Exp.Hematol., 36, No.4, pp. 390-400, 0301-472X 
Maurer, M. & von, S. E. (2004). Macrophage inflammatory protein-1. Int.J.Biochem.Cell Biol., 
36, No.10, pp. 1882-1886, 1357-2725 
McDonald, I. M.; Austin, C.; Buck, I. M.; Dunstone, D. J.; Gaffen, J.; Griffin, E.; Harper, E. A.; 
Hull, R. A.; Kalindjian, S. B.; Linney, I. D.; Low, C. M.; Patel, D.; Pether, M. J.; 
Raynor, M.; Roberts, S. P.; Shaxted, M. E.; Spencer, J.; Steel, K. I.; Sykes, D. A.; 
Wright, P. T. & Xun, W. (2007). Discovery and characterization of novel, potent, 
non-peptide parathyroid hormone-1 receptor antagonists. J.Med.Chem., 50, No.20, 
pp. 4789-4792, 0022-2623 
Meghji, S.; Crean, S. J.; Hill, P. A.; Sheikh, M.; Nair, S. P.; Heron, K.; Henderson, B.; Mawer, 
E. B. & Harris, M. (1998). Surface-associated protein from Staphylococcus aureus 
stimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology. 
Br.J.Rheumatol., 37, No.10, pp. 1095-1101, 0263-7103 
Mellanby, R. J.; Craig, R.; Evans, H. & Herrtage, M. E. (2006). Plasma concentrations of 
parathyroid hormone-related protein in dogs with potential disorders of calcium 
metabolism. Vet.Rec., 159, No.25, pp. 833-838, 0042-4900 
Menu, E.; De, L. E.; De, R. H.; Coulton, L.; Imanishi, T.; Miyashita, K.; Van, V. E.; Van, R., I; 
Van, C. B.; Horuk, R.; Croucher, P. & Vanderkerken, K. (2006). Role of CCR1 and 
CCR5 in homing and growth of multiple myeloma and in the development of 
osteolytic lesions: a study in the 5TMM model. Clin.Exp.Metastasis, 23, No.5-6, pp. 
291-300, 0262-0898 
Merkel, K. D.; Erdmann, J. M.; McHugh, K. P.; Abu-Amer, Y.; Ross, F. P. & Teitelbaum, S. L. 
(1999). Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. 
Am.J.Pathol., 154, No.1, pp. 203-210, 0002-9440 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
201 
Mitra-Kaushik, S.; Harding, J.; Hess, J.; Schreiber, R. & Ratner, L. (2004a). Enhanced 
tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood, 
104, No.10, pp. 3305-3311, 0006-4971 
Mitra-Kaushik, S.; Harding, J. C.; Hess, J. L. & Ratner, L. (2004b). Effects of the proteasome 
inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor 
transplants. Blood, 104, No.3, pp. 802-809, 0006-4971 
Mizuno, A.; Amizuka, N.; Irie, K.; Murakami, A.; Fujise, N.; Kanno, T.; Sato, Y.; Nakagawa, 
N.; Yasuda, H.; Mochizuki, S.; Gomibuchi, T.; Yano, K.; Shima, N.; Washida, N.; 
Tsuda, E.; Morinaga, T.; Higashio, K. & Ozawa, H. (1998). Severe osteoporosis in 
mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. 
Biochem.Biophys.Res.Commun., 247, No.3, pp. 610-615, 0006-291X 
Mundy, G. R. & Martin, T. J. (1982). The hypercalcemia of malignancy: pathogenesis and 
management. Metabolism, 31, No.12, pp. 1247-1277, 0026-0495 
Nadella, M. V.; Dirksen, W. P.; Nadella, K. S.; Shu, S.; Cheng, A. S.; Morgenstern, J. A.; 
Richard, V.; Fernandez, S. A.; Huang, T. H.; Guttridge, D. & Rosol, T. J. (2007). 
Transcriptional regulation of parathyroid hormone-related protein promoter P2 by 
NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia, 21, No.8, pp. 1752-
1762, 0887-6924 
Nadella, M. V.; Kisseberth, W. C.; Nadella, K. S.; Thudi, N. K.; Thamm, D. H.; McNiel, E. A.; 
Yilmaz, A.; Boris-Lawrie, K. & Rosol, T. J. (2008). NOD/SCID mouse model of 
canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine 
gene expression profiling and in vivo bioluminescent imaging. Vet.Comp Oncol., 6, 
No.1, pp. 39-54, 1476-5810 
Narimatsu, H.; Morishita, Y.; Shimada, K.; Ozeki, K.; Kohno, A.; Kato, Y. & Nagasaka, T. 
(2003). Primary cutaneous diffuse large B cell lymphoma: a clinically aggressive 
case. Intern.Med., 42, No.4, pp. 354-357, 0918-2918 
Nasr, R.; El-Sabban, M. E.; Karam, J. A.; Dbaibo, G.; Kfoury, Y.; Arnulf, B.; Lepelletier, Y.; 
Bex, F.; de, T. H.; Hermine, O. & Bazarbachi, A. (2005). Efficacy and mechanism of 
action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I 
associated adult T-cell leukemia/lymphoma. Oncogene, 24, No.3, pp. 419-430, 
0950-9232 
Nosaka, K.; Miyamoto, T.; Sakai, T.; Mitsuya, H.; Suda, T. & Matsuoka, M. (2002). 
Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor 
activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood, 99, 
No.2, pp. 634-640, 0006-4971 
Oba, Y.; Lee, J. W.; Ehrlich, L. A.; Chung, H. Y.; Jelinek, D. F.; Callander, N. S.; Horuk, R.; 
Choi, S. J. & Roodman, G. D. (2005). MIP-1alpha utilizes both CCR1 and CCR5 to 
induce osteoclast formation and increase adhesion of myeloma cells to marrow 
stromal cells. Exp.Hematol., 33, No.3, pp. 272-278, 0301-472X 
Okada, Y.; Tsukada, J.; Nakano, K.; Tonai, S.; Mine, S. & Tanaka, Y. (2004). Macrophage 
inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. 
J.Bone Miner.Res., 19, No.7, pp. 1105-1111, 0884-0431 
www.intechopen.com
 
T-Cell Leukemia 
 
202 
Olivo, R. A.; Martins, F. F.; Soares, S. & Moraes-Souza, H. (2008). Adult T-cell 
leukemia/lymphoma: report of two cases. Rev.Soc.Bras.Med.Trop., 41, No.3, pp. 
288-292, 0037-8682 
Oyajobi, B. O.; Franchin, G.; Williams, P. J.; Pulkrabek, D.; Gupta, A.; Munoz, S.; Grubbs, B.; 
Zhao, M.; Chen, D.; Sherry, B. & Mundy, G. R. (2003). Dual effects of macrophage 
inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 
model of myeloma bone disease. Blood, 102, No.1, pp. 311-319, 0006-4971 
Parrula, C.; Zimmerman, B.; Nadella, P.; Shu, S.; Rosol, T.; Fernandez, S.; Lairmore, M. & 
Niewiesk, S. (2009). Expression of tumor invasion factors determines systemic 
engraftment and induction of humoral hypercalcemia in a mouse model of adult T-
cell leukemia. Vet.Pathol., 46, No.5, pp. 1003-1014, 0300-9858 
Pennisi, A.; Li, X.; Ling, W.; Khan, S.; Zangari, M. & Yaccoby, S. (2009). The proteasome 
inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation 
in myelomatous and nonmyelomatous bones in vivo. Am.J.Hematol., 84, No.1, pp. 
6-14, 0361-8609 
Phillips, K. E.; Herring, B.; Wilson, L. A.; Rickford, M. S.; Zhang, M.; Goldman, C. K.; Tso, J. 
Y. & Waldmann, T. A. (2000). IL-2Ralpha-Directed monoclonal antibodies provide 
effective therapy in a murine model of adult T-cell leukemia by a mechanism other 
than blockade of IL-2/IL-2Ralpha interaction. Cancer Res., 60, No.24, pp. 6977-6984, 
0008-5472 
Qiang, Y. W.; Hu, B.; Chen, Y.; Zhong, Y.; Shi, B.; Barlogie, B. & Shaughnessy, J. D., Jr. (2009). 
Bortezomib induces osteoblast differentiation via Wnt-independent activation of 
beta-catenin/TCF signaling. Blood, 113, No.18, pp. 4319-4330, 0006-4971 
Quinn, J. M. & Gillespie, M. T. (2005). Modulation of osteoclast formation. 
Biochem.Biophys.Res.Commun., 328, No.3, pp. 739-745, 0006-291X 
Richard, V.; Lairmore, M. D.; Green, P. L.; Feuer, G.; Erbe, R. S.; Albrecht, B.; D'Souza, C.; 
Keller, E. T.; Dai, J. & Rosol, T. J. (2001). Humoral hypercalcemia of malignancy: 
severe combined immunodeficient/beige mouse model of adult T-cell lymphoma 
independent of human T-cell lymphotropic virus type-1 tax expression. 
Am.J.Pathol., 158, No.6, pp. 2219-2228, 0002-9440 
Richard, V.; Nadella, M. V.; Green, P. L.; Lairmore, M. D.; Feuer, G.; Foley, J. G. & Rosol, T. J. 
(2005). Transcriptional regulation of parathyroid hormone-related protein promoter 
P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia, 19, No.7, pp. 1175-
1183, 0887-6924 
Roodman, G. D. (1997). Mechanisms of bone lesions in multiple myeloma and lymphoma. 
Cancer, 80, No.8 Suppl, pp. 1557-1563, 0008-543X 
Roodman, G. D. (2001). Biology of osteoclast activation in cancer. J.Clin.Oncol., 19, No.15, 
pp. 3562-3571, 0732-183X 
Rosol, T. J.; Nagode, L. A.; Couto, C. G.; Hammer, A. S.; Chew, D. J.; Peterson, J. L.; Ayl, R. 
D.; Steinmeyer, C. L. & Capen, C. C. (1992). Parathyroid hormone (PTH)-related 
protein, PTH, and 1,25-dihydroxyvitamin D in dogs with cancer-associated 
hypercalcemia. Endocrinology, 131, No.3, pp. 1157-1164, 0013-7227 
Ruddle, N. H.; Li, C. B.; Horne, W. C.; Santiago, P.; Troiano, N.; Jay, G.; Horowitz, M. & 
Baron, R. (1993). Mice transgenic for HTLV-I LTR-tax exhibit tax expression in 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
203 
bone, skeletal alterations, and high bone turnover. Virology, 197, No.1, pp. 196-204, 
0042-6822 
Sagara, Y.; Inoue, Y.; Sagara, Y. & Kashiwagi, S. (2009). Involvement of molecular mimicry 
between human T-cell leukemia virus type 1 gp46 and osteoprotegerin in induction 
of hypercalcemia. Cancer Sci., 100, No.3, pp. 490-496, 1347-9032 
Saidak, Z.; Mentaverri, R. & Brown, E. M. (2009). The role of the calcium-sensing receptor in 
the development and progression of cancer. Endocr.Rev., 30, No.2, pp. 178-195, 
0163-769X 
Sato, K.; Onuma, E.; Yocum, R. C. & Ogata, E. (2003). Treatment of malignancy-associated 
hypercalcemia and cachexia with humanized anti-parathyroid hormone-related 
protein antibody. Semin.Oncol., 30, No.5 Suppl 16, pp. 167-173, 0093-7754 
Sato, K.; Suematsu, A.; Okamoto, K.; Yamaguchi, A.; Morishita, Y.; Kadono, Y.; Tanaka, S.; 
Kodama, T.; Akira, S.; Iwakura, Y.; Cua, D. J. & Takayanagi, H. (2006). Th17 
functions as an osteoclastogenic helper T cell subset that links T cell activation and 
bone destruction. J.Exp.Med., 203, No.12, pp. 2673-2682, 0022-1007 
Satou, Y.; Nosaka, K.; Koya, Y.; Yasunaga, J. I.; Toyokuni, S. & Matsuoka, M. (2004). 
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell 
leukemia cells both in vivo and in vitro. Leukemia, 18, No.8, pp. 1357-1363, 
0887-6924 
Schwarz, E. M. & Ritchlin, C. T. (2007). Clinical development of anti-RANKL therapy. 
Arthritis Res.Ther., 9 Suppl 1, p. S7, 1478-6354 
Seymour, J. F. & Gagel, R. F. (1993). Calcitriol: the major humoral mediator of hypercalcemia 
in Hodgkin's disease and non-Hodgkin's lymphomas. Blood, 82, No.5, pp. 1383-
1394, 0006-4971 
Sharan, K.; Siddiqui, J. A.; Swarnkar, G. & Chattopadhyay, N. (2008). Role of calcium-
sensing receptor in bone biology. Indian J.Med.Res., 127, No.3, pp. 274-286, 
0971-5916 
Sharma, V. & May, C. C. (1999). Human T-cell lymphotrophic virus type-I tax gene induces 
secretion of human macrophage inflammatory protein-1alpha. 
Biochem.Biophys.Res.Commun., 262, No.2, pp. 429-432, 0006-291X 
Shu, S. T.; Martin, C. K.; Thudi, N. K.; Dirksen, W. P. & Rosol, T. J. (2010). Osteolytic bone 
resorption in adult T-cell leukemia/lymphoma. Leuk.Lymphoma, 51, No.4, pp. 
702-714, 1042-8194 
Shu, S. T.; Nadella, M. V.; Dirksen, W. P.; Fernandez, S. A.; Thudi, N. K.; Werbeck, J. L.; 
Lairmore, M. D. & Rosol, T. J. (2007). A novel bioluminescent mouse model and 
effective therapy for adult T-cell leukemia/lymphoma. Cancer Res., 67, No.24, pp. 
11859-11866, 0008-5472 
Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M.; Chang, M. S.; Luthy, R.; Nguyen, H. 
Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; DeRose, M.; Elliott, R.; 
Colombero, A.; Tan, H. L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-
Gegg, L.; Hughes, T. M.; Hill, D.; Pattison, W.; Campbell, P.; Sander, S.; Van, G.; 
Tarpley, J.; Derby, P.; Lee, R. & Boyle, W. J. (1997). Osteoprotegerin: a novel 
secreted protein involved in the regulation of bone density. Cell, 89, No.2, pp. 309-
319, 0092-8674 
www.intechopen.com
 
T-Cell Leukemia 
 
204 
Sims, N. A.; Jenkins, B. J.; Quinn, J. M.; Nakamura, A.; Glatt, M.; Gillespie, M. T.; Ernst, M. & 
Martin, T. J. (2004). Glycoprotein 130 regulates bone turnover and bone size by 
distinct downstream signaling pathways. J.Clin.Invest, 113, No.3, pp. 379-389, 
0021-9738 
Sordillo, E. M. & Pearse, R. N. (2003). RANK-Fc: a therapeutic antagonist for RANK-L in 
myeloma. Cancer, 97, No.3 Suppl, pp. 802-812, 0008-543X 
Stewart, A. F. (2002). Hyperparathyroidism, humoral hypercalcemia of malignancy, and the 
anabolic actions of parathyroid hormone and parathyroid hormone-related protein 
on the skeleton. J.Bone Miner.Res., 17, No.5, pp. 758-762, 0884-0431 
Stewart, A. F. (2005). Clinical practice. Hypercalcemia associated with cancer. N.Engl.J.Med., 
352, No.4, pp. 373-379, 0028-4793 
Suva, L. J.; Winslow, G. A.; Wettenhall, R. E.; Hammonds, R. G.; Moseley, J. M.; Diefenbach-
Jagger, H.; Rodda, C. P.; Kemp, B. E.; Rodriguez, H.; Chen, E. Y. & . (1987). A 
parathyroid hormone-related protein implicated in malignant hypercalcemia: 
cloning and expression. Science, 237, No.4817, pp. 893-896, 0036-8075 
Takaori-Kondo, A.; Imada, K.; Yamamoto, I.; Kunitomi, A.; Numata, Y.; Sawada, H. & 
Uchiyama, T. (1998). Parathyroid hormone-related protein-induced hypercalcemia 
in SCID mice engrafted with adult T-cell leukemia cells. Blood, 91, No.12, pp. 4747-
4751, 0006-4971 
Takayanagi, H. (2007). Osteoimmunology: shared mechanisms and crosstalk between the 
immune and bone systems. Nat.Rev.Immunol., 7, No.4, pp. 292-304, 1474-1733 
Takeuchi, Y.; Fukumoto, S.; Nakayama, K.; Tamura, Y.; Yanagisawa, A. & Fujita, T. (2002). 
Parathyroid hormone-related protein induced coupled increases in bone formation 
and resorption markers for 7 years in a patient with malignant islet cell tumors. 
J.Bone Miner.Res., 17, No.5, pp. 753-757, 0884-0431 
Tan, C. & Waldmann, T. A. (2002). Proteasome inhibitor PS-341, a potential therapeutic 
agent for adult T-cell leukemia. Cancer Res., 62, No.4, pp. 1083-1086, 0008-5472 
Tanaka, S.; Takahashi, N.; Udagawa, N.; Tamura, T.; Akatsu, T.; Stanley, E. R.; Kurokawa, T. 
& Suda, T. (1993). Macrophage colony-stimulating factor is indispensable for both 
proliferation and differentiation of osteoclast progenitors. J.Clin.Invest, 91, No.1, 
pp. 257-263, 0021-9738 
Terpos, E.; Heath, D. J.; Rahemtulla, A.; Zervas, K.; Chantry, A.; Anagnostopoulos, A.; Pouli, 
A.; Katodritou, E.; Verrou, E.; Vervessou, E. C.; Dimopoulos, M. A. & Croucher, P. 
I. (2006). Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear 
factor-kappaB ligand concentrations and normalises indices of bone remodelling in 
patients with relapsed multiple myeloma. Br.J.Haematol., 135, No.5, pp. 688-692, 
0007-1048 
Tsubaki, M.; Kato, C.; Manno, M.; Ogaki, M.; Satou, T.; Itoh, T.; Kusunoki, T.; Tanimori, Y.; 
Fujiwara, K.; Matsuoka, H. & Nishida, S. (2007). Macrophage inflammatory 
protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB 
ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts 
through MAPK and PI3K/Akt pathways. Mol.Cell Biochem., 304, No.1-2, pp. 53-60, 
0300-8177 
www.intechopen.com
 
Mechanisms of Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma 
 
205 
Unal, S.; Durmaz, E.; Erkocoglu, M.; Bayrakci, B.; Bircan, O.; Alikasifoglu, A. & Cetin, M. 
(2008). The rapid correction of hypercalcemia at presentation of acute 
lymphoblastic leukemia using high-dose methylprednisolone. Turk.J.Pediatr., 50, 
No.2, pp. 171-175, 0041-4301 
Vanderschueren, B.; Dumon, J. C.; Oleffe, V.; Heymans, C.; Gerain, J. & Body, J. J. (1994). 
Circulating concentrations of interleukin-6 in cancer patients and their pathogenic 
role in tumor-induced hypercalcemia. Cancer Immunol.Immunother., 39, No.5, pp. 
286-290, 0340-7004 
von Metzler, I.; Krebbel, H.; Hecht, M.; Manz, R. A.; Fleissner, C.; Mieth, M.; Kaiser, M.; 
Jakob, C.; Sterz, J.; Kleeberg, L.; Heider, U. & Sezer, O. (2007). Bortezomib inhibits 
human osteoclastogenesis. Leukemia, 21, No.9, pp. 2025-2034, 0887-6924 
Wano, Y.; Hattori, T.; Matsuoka, M.; Takatsuki, K.; Chua, A. O.; Gubler, U. & Greene, W. C. 
(1987). Interleukin 1 gene expression in adult T cell leukemia. J.Clin.Invest, 80, 
No.3, pp. 911-916, 0021-9738 
Watanabe, T.; Yamaguchi, K.; Takatsuki, K.; Osame, M. & Yoshida, M. (1990). Constitutive 
expression of parathyroid hormone-related protein gene in human T cell leukemia 
virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-
activated by HTLV-1 tax gene. J.Exp.Med., 172, No.3, pp. 759-765, 0022-1007 
Weitzmann, M. N. & Pacifici, R. (2005). The role of T lymphocytes in bone metabolism. 
Immunol.Rev., 208, pp. 154-168, 0105-2896 
Wysolmerski, J. J.; Philbrick, W. M.; Dunbar, M. E.; Lanske, B.; Kronenberg, H. & Broadus, 
A. E. (1998). Rescue of the parathyroid hormone-related protein knockout mouse 
demonstrates that parathyroid hormone-related protein is essential for mammary 
gland development. Development, 125, No.7, pp. 1285-1294, 0950-1991 
Xu, Z.; Hurchla, M. A.; Deng, H.; Uluckan, O.; Bu, F.; Berdy, A.; Eagleton, M. C.; Heller, E. 
A.; Floyd, D. H.; Dirksen, W. P.; Shu, S.; Tanaka, Y.; Fernandez, S. A.; Rosol, T. J. & 
Weilbaecher, K. N. (2009). Interferon-gamma targets cancer cells and osteoclasts to 
prevent tumor-associated bone loss and bone metastases. J.Biol.Chem., 284, No.7, 
pp. 4658-4666, 0021-9258 
Yamaguchi, T. (2008). The calcium-sensing receptor in bone. J.Bone Miner.Metab, 26, No.4, 
pp. 301-311, 0914-8779 
Yang, X.; Halladay, D.; Onyia, J. E.; Martin, T. J. & Chandrasekhar, S. (2002). Protein Kinase 
C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like 
cells. Biochem.Biophys.Res.Commun., 290, No.1, pp. 42-46, 0006-291X 
Yarbro, C. E.; Frogge, M. H. & Goodman, M. (2003). Cancer Symptom Management, p. 455, 
0763721425 
Zaidi, M.; Inzerillo, A. M.; Moonga, B. S.; Bevis, P. J. & Huang, C. L. (2002). Forty years of 
calcitonin--where are we now? A tribute to the work of Iain Macintyre, FRS. Bone, 
30, No.5, pp. 655-663, 8756-3282 
Zhang, J.; Dai, J.; Yao, Z.; Lu, Y.; Dougall, W. & Keller, E. T. (2003). Soluble receptor activator 
of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer 
Res., 63, No.22, pp. 7883-7890, 0008-5472 
www.intechopen.com
 
T-Cell Leukemia 
 
206 
Zhong, Y.; Armbrecht, H. J. & Christakos, S. (2009). Calcitonin, a regulator of the 25-
hydroxyvitamin D3 1alpha-hydroxylase gene. J.Biol.Chem., 284, No.17, pp. 11059-
11069, 0021-9258 
Zlotnik, A. & Yoshie, O. (2000). Chemokines: a new classification system and their role in 
immunity. Immunity., 12, No.2, pp. 121-127, 1074-7613 
www.intechopen.com
T-Cell Leukemia
Edited by Dr Olga Babusikova
ISBN 978-953-307-400-9
Hard cover, 234 pages
Publisher InTech
Published online 26, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The purpose of this book is to provide a comprehensive review of the scientific advances in T-cell
malignancies and to highlight the most relevant findings that will help the reader understand both basic
mechanisms of the disease and future directions that are likely to lead to novel therapies. In order to assure a
thorough approach to these problems, contributors include basic scientists, translational researchers and
clinicians who are experts in this field. Thus, the target audience for this book includes both basic scientists
who will use this book as a review of the advances in our fundamental knowledge of the molecular
mechanisms of T-cell malignancies, as well as clinicians who will use this book as a tool to understand
rationales for the development of novel treatments for these diseases.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Sherry T. Shu, Wessel P. Dirksen, Katherine N. Weibaecher and Thomas J. Rosol (2011). Mechanisms of
Humoral Hypercalcemia of Malignancy in Leukemia/Lymphoma, T-Cell Leukemia, Dr Olga Babusikova (Ed.),
ISBN: 978-953-307-400-9, InTech, Available from: http://www.intechopen.com/books/t-cell-
leukemia/mechanisms-of-humoral-hypercalcemia-of-malignancy-in-leukemia-lymphoma
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
